Compositions and methods for treating glaucoma

• US 20060280774A1
• Filed: 05/23/2006
• Published: 12/14/2006
• Est. Priority Date: 06/02/1995
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Wong, Vernon, Peng, Lin
• Application Number:
  US11/440,204
• Publication Number:
  US 20060280774A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/204 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Implants and methods are provided for modulating wound healing and controlling infection to improve the success of glaucoma filtration surgery. Formulations of one or more therapeutically active agents and a biodegradable polymer provide a substantially constant rate of release for an extended period of time.

Claims

1-19. -19. (canceled)

20. A biodegradable implant for placement in an eye, comprising:

a steroid and a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the steroid makes up between about 1 percent by weight and about 80 percent by weight of the biodegradable implant, and wherein the implant releases at least about 20% of the steroid within about 1 week when measured under infinite sink conditions in vitro.

21. The implant of claim 20, wherein the steroid is dexamethasone.

22. The implant of claim 21, wherein the dexamethasone makes up about 50 percent by weight of the implant.

23. The implant of claim 20, wherein the steroid is located within a polylactic acid polyglycolic acid (PLGA) copolymer matrix.

24. The implant of claim 20, wherein the implant releases at least about 50% of the dexamethasone within 2 weeks when measured under infinite sink conditions in vitro.

25. The implant of claim 20, wherein the implant releases at least about 80% of the dexamethasone within about 3 weeks when measured under infinite sink conditions in vitro.

26. The implant of claim 20, wherein the implant is configured as a disc.

27. The implant of claim 26, wherein the implant has a thickness of about 0.15 mm.

28. The implant of claim 26, wherein the implant has a diameter of about 2.5 mm.

29. The implant of claim 20, wherein the steroid is dexamethasone and makes up about 20% by weight of the implant.

30. The implant of claim 20, wherein the implant is sized to be placed intrasclerally or intralammellary in an eye.

31. The implant of claim 20, further comprising an additional different therapeutic agent selected from the group consisting of anti-inflammatory agents, anti-proliferative agents, anti-viral agents, and anti-bacterial agents.

32. The implant of claim 20, further comprising 5-flurouracil mixed with the steroid and the PLGA copolymer.

33. The implant of claim 20, further comprising ciprofloxacin mixed with the steroid and the PLGA copolymer.

34. The implant of claim 20 formed by an extrusion process.

35. The implant of claim 20, further comprising a release modifier.

36. The implant of claim 20, which includes no release modifier.

37. A biodegradable implant for placement in an eye, comprising:

a mixture of a non-inflammatory agent and a biodegradable polymer, wherein the non-inflammatory agent makes up between about 1 percent by weight and about 80 percent by weight of the biodegradable implant, and wherein the implant releases the non-inflammatory agent at a substantially constant rate for at least about three weeks as the implant degrades.

38. The implant of claim 37, wherein the biodegradable polymer is a copolymer.

39. The implant of claim 37, wherein the biodegradable polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.

40. The implant of claim 37, wherein the implant releases at least about 10% of the non-inflammatory agent within about 3 days.

41. The implant of claim 40, wherein the implant releases at least about 50% of the non-inflammatory agent within about 2 weeks.

42. The implant of claim 41, wherein the release of the non-inflammatory agent is measured under infinite sink conditions in vitro.

43. The implant of claim 41, wherein the implant releases at least about 80% of the non-inflammatory agent within about 3 weeks.

44. The implant of claim 37, wherein the non-inflammatory agent is a steroid.

45. The implant of claim 44, wherein the steroid is dexamethasone.

46. The implant of claim 37, wherein the implant is configured as a disc.

47. The implant of claim 37, further comprising an additional different therapeutic agent selected from the group consisting of anti-inflammatory agents, anti-proliferative agents, anti-viral agents, and anti-bacterial agents.

48. The implant of claim 37, wherein the non-inflammatory agent is dexamethasone provided in an amount of about 50% by weight of the implant.

49. The implant of claim 37, further comprising a release modifier mixed with the non-inflammatory agent and the biodegradable polymer.

50. The implant of claim 37, which includes no release modifier.

51. The implant of claim 37, wherein the mixture is an extruded mixture.